News Related to Bempedoic acid

Related coverage linked through entity extraction aliases.

Merck to Present Cardio-Pulmonary Pipeline Data at ACC.26, Including Phase 3 Enlicitide Results

Mar 17, 2026

Merck will present late-breaking clinical data from its cardio-pulmonary pipeline at ACC.26, including positive Phase 3 results for enlicitide, an investigational oral PCSK9 inhibitor, and Phase 2 data for WINREVAIR in heart failure patients.

Blue Jet Healthcare Downgraded on Weak Execution, Pipeline Concerns

Mar 01, 2026

JPMorgan downgraded Blue Jet Healthcare to Underweight with a ₹330 target price, citing weak contrast media execution, bempedoic acid competitive threats, and a thin late-stage pipeline with no launches expected for two years.